These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 17125207)
41. Matched molecular pairs as a guide in the optimization of pharmaceutical properties; a study of aqueous solubility, plasma protein binding and oral exposure. Leach AG; Jones HD; Cosgrove DA; Kenny PW; Ruston L; MacFaul P; Wood JM; Colclough N; Law B J Med Chem; 2006 Nov; 49(23):6672-82. PubMed ID: 17154498 [TBL] [Abstract][Full Text] [Related]
42. Molecular modeling of hydration in drug design. Mancera RL Curr Opin Drug Discov Devel; 2007 May; 10(3):275-80. PubMed ID: 17554853 [TBL] [Abstract][Full Text] [Related]
43. Using classification structure pharmacokinetic relationship (SCPR) method to predict drug bioavailability based on grid-search support vector machine. Wang J; Du H; Yao X; Hu Z Anal Chim Acta; 2007 Oct; 601(2):156-63. PubMed ID: 17920387 [TBL] [Abstract][Full Text] [Related]
44. Evaluation of a novel method to estimate absolute bioavailability of drugs from oral data. Hinderling PH Biopharm Drug Dispos; 2003 Jan; 24(1):1-16. PubMed ID: 12516074 [TBL] [Abstract][Full Text] [Related]
45. A cluster-based strategy for assessing the overlap between large chemical libraries and its application to a recent acquisition. Engels MF; Gibbs AC; Jaeger EP; Verbinnen D; Lobanov VS; Agrafiotis DK J Chem Inf Model; 2006; 46(6):2651-60. PubMed ID: 17125205 [TBL] [Abstract][Full Text] [Related]
46. Virtual high-throughput screening of molecular databases. Seifert MH; Kraus J; Kramer B Curr Opin Drug Discov Devel; 2007 May; 10(3):298-307. PubMed ID: 17554856 [TBL] [Abstract][Full Text] [Related]
47. Drug discovery in the kinase inhibitory field using the Nested Chemical Library technology. Kéri G; Székelyhidi Z; Bánhegyi P; Varga Z; Hegymegi-Barakonyi B; Szántai-Kis C; Hafenbradl D; Klebl B; Muller G; Ullrich A; Erös D; Horváth Z; Greff Z; Marosfalvi J; Pató J; Szabadkai I; Szilágyi I; Szegedi Z; Varga I; Wáczek F; Orfi L Assay Drug Dev Technol; 2005 Oct; 3(5):543-51. PubMed ID: 16305311 [TBL] [Abstract][Full Text] [Related]
48. Lead optimization via high-throughput molecular docking. Joseph-McCarthy D; Baber JC; Feyfant E; Thompson DC; Humblet C Curr Opin Drug Discov Devel; 2007 May; 10(3):264-74. PubMed ID: 17554852 [TBL] [Abstract][Full Text] [Related]
49. A novel QSPR model for prediction of lower flammability limits of organic compounds based on support vector machine. Pan Y; Jiang J; Wang R; Cao H; Cui Y J Hazard Mater; 2009 Sep; 168(2-3):962-9. PubMed ID: 19329246 [TBL] [Abstract][Full Text] [Related]
50. Influence of molecular properties on oral bioavailability of lipophilic drugs - mapping of bulkiness and different measures of polarity. Kuentz MT; Arnold Y Pharm Dev Technol; 2009; 14(3):312-20. PubMed ID: 19235630 [TBL] [Abstract][Full Text] [Related]
51. The graphical representation of ADME-related molecule properties for medicinal chemists. Ritchie TJ; Ertl P; Lewis R Drug Discov Today; 2011 Jan; 16(1-2):65-72. PubMed ID: 21074634 [TBL] [Abstract][Full Text] [Related]
52. Exploiting QSAR models in lead optimization. Gedeck P; Lewis RA Curr Opin Drug Discov Devel; 2008 Jul; 11(4):569-75. PubMed ID: 18600573 [TBL] [Abstract][Full Text] [Related]
53. Complex molecules: do they add value? Selzer P; Roth HJ; Ertl P; Schuffenhauer A Curr Opin Chem Biol; 2005 Jun; 9(3):310-6. PubMed ID: 15939334 [TBL] [Abstract][Full Text] [Related]
54. QSAR modeling of human serum protein binding with several modeling techniques utilizing structure-information representation. Votano JR; Parham M; Hall LM; Hall LH; Kier LB; Oloff S; Tropsha A J Med Chem; 2006 Nov; 49(24):7169-81. PubMed ID: 17125269 [TBL] [Abstract][Full Text] [Related]
55. Predicting oral druglikeness by iterative stochastic elimination. Rayan A; Marcus D; Goldblum A J Chem Inf Model; 2010 Mar; 50(3):437-45. PubMed ID: 20170135 [TBL] [Abstract][Full Text] [Related]
56. A scoring scheme for discriminating between drugs and nondrugs. Sadowski J; Kubinyi H J Med Chem; 1998 Aug; 41(18):3325-9. PubMed ID: 9719584 [TBL] [Abstract][Full Text] [Related]
57. [The importance of micronization in the design of dosage forms I. Theoretical and biopharmaceutical aspects]. Antal I Acta Pharm Hung; 2006; 76(2):95-103. PubMed ID: 17094668 [TBL] [Abstract][Full Text] [Related]
58. Metal complexes in medicinal chemistry: new vistas and challenges in drug design. Thompson KH; Orvig C Dalton Trans; 2006 Feb; (6):761-4. PubMed ID: 16437168 [TBL] [Abstract][Full Text] [Related]
59. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Blagden N; de Matas M; Gavan PT; York P Adv Drug Deliv Rev; 2007 Jul; 59(7):617-30. PubMed ID: 17597252 [TBL] [Abstract][Full Text] [Related]